Incyte closes $2bn Vega Therapeutics deal as VGA039 reshapes VWD strategy
Incyte has acquired Vega Therapeutics and Phase 3 VWD antibody VGA039. Explore the clinical promise, deal strategy and risks ahead.
Pharma & Biotech
Pharma & Biotech
Can RenSuper help Biocytogen reduce the bottlenecks in antibody development?
Biocytogen is turning antibody discovery into an AI-led industrial workflow. RenSuper could speed biologics R&D, but validation risk remains.
Pharma & Biotech
Ankyra Therapeutics targets a bigger immunotherapy problem with anchored monoclonal antibodies
Cancer antibodies can be powerful but toxic. Ankyra’s anchored platform asks whether local retention can widen immunotherapy’s safety window.
Pharma & Biotech
Harbour BioMed HBM9378 Phase I data: does long-acting TSLP inhibition change asthma treatment economics?
Harbour BioMed’s HBM9378 Phase I data shows long half-life and safety. Find out what this means for asthma, COPD, and TSLP competition.
Pharma & Biotech
Can NovelMed Therapeutics challenge established PNH drugs with its Bb-targeting antibody Ruxoprubart?
NovelMed Therapeutics advances Ruxoprubart for paroxysmal nocturnal hemoglobinuria with Phase II data and a new subcutaneous trial. Discover what comes next.
Pharma & Biotech
Why Precision Biologics is betting on tumor-specific neoepitopes to reshape monoclonal antibody cancer therapy
Precision Biologics highlights tumor-specific monoclonal antibodies at Festival of Biologics USA. Discover how neoepitope targeting could reshape cancer therapy.
Pharma & Biotech
Could Invivyd’s VYD2311 offer a safer alternative to mRNA COVID vaccines for vulnerable groups?
Invivyd’s LIBERTY trial could reshape COVID prophylaxis by comparing VYD2311 antibody safety with mRNA vaccines. See what’s at stake for regulators.
Pharma & Biotech
What Mirum’s Bluejay acquisition reveals about its long-term liver disease strategy
Mirum adds brelovitug in HDV through Bluejay deal. See how this could redefine rare liver disease leadership ahead of AZURE Phase 3 results in 2026.
Pharma & Biotech
How Brazil’s GMP approval for pembrolizumab biosimilar changes global biosimilar dynamics
Blau Farmacêutica’s pembrolizumab biosimilar earns ANVISA GMP approval—see what this means for Brazil’s global position in cancer immunotherapy.
Pharma & Biotech
What Rakuten Medical’s deal with LOTTE Biologics signals for photoimmunotherapy scale-up
Rakuten Medical taps LOTTE Biologics for global supply of its Alluminox cancer platform. Find out what this deal means for photoimmunotherapy’s future.